IC 100 

IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003^[1][2].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

IC 100 (0.001-1 μg/mL) dose-dependently inhibits IL-1β release in LPS/ATP-stimulated whole human blood, with significant inhibition observed at 1.0 and 0.1 μg/mL^[2].
IC 100 (1 μg/mL) is rapidly internalized into iBMDM, remains detectable intracellularly for at least 2 hours, and is partially recycled and secreted back into the extracellular medium^[2].
IC 100 (5 μg/mL) can bind to intracellular ASC and TRIM21 in THP-1 cells and iBMDM, directly interact with purified TRIM21 in a cell-free system, evade degradation through the TRIM21-mediated ADIN pathway, and remain detectable in A549 WT and TRIM21 KO cells for at least 3 days after cellular uptake^[2].
IC 100 (3 μM; 1 hour pre-incubation prior to ASC PYD filament formation; 1 hour incubation with pre-formed filaments for immunogold labeling) specifically binds to ASC PYD filaments and alters their architecture, without inhibiting TEV protease activity or binding to non-ASC control filaments^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

IC 100 (30-45 mg/kg; i.p.; every 4 days; 27 days) significantly improves functional outcomes in MOG-induced EAE, with 30 mg/kg additionally suppressing spinal cord immune cell infiltration and microglia activation^[1].
IC 100 (100 μg per animal; i.v.; single dose) exhibits broad tissue distribution in healthy mice, crossing the blood-brain barrier to penetrate brain and spinal cord parenchyma, with significant accumulation in multiple peripheral tissues (excluding thyroid and pancreas) at 48 hours post-administration^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

29108  [NCBI]

Q9ULZ3

PYCARD

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Desu HL, et al. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis. J Neuroinflammation. 2020;17(1):143. Published 2020 May 4.  [Content Brief]

  [2]. de Rivero Vaccari JP, et al. Mechanism of action of IC 100, a humanized IgG4 monoclonal antibody targeting apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC). Transl Res. 2023;251:27-40.  [Content Brief]